Search

Your search keyword '"Blanz, J."' showing total 98 results

Search Constraints

Start Over You searched for: Author "Blanz, J." Remove constraint Author: "Blanz, J."
98 results on '"Blanz, J."'

Search Results

1. Antennas & Propagation

4. Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study

5. Abstract

6. Scientific Proceedings Second International Symposium on Cytostatic Drug Resistance

10. Leukoencephalopathy upon disruption of the chloride channel ClC-2

11. Enzyme replacement therapy for alpha-mannosidosis:12 months follow-up of a single centre, randomised, multiple dose study

20. Biotransformation of CI-937 in primary cultures of rat hepatocytes. Formation of glutathione conjugates.

21. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice

28. Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.

29. Preclinical pharmacokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment.

30. Genetic LAMP2 deficiency accelerates the age-associated formation of basal laminar deposits in the retina.

31. Long-term enzyme replacement therapy improves neurocognitive functioning and hippocampal synaptic plasticity in immune-tolerant alpha-mannosidosis mice.

32. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease.

33. Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.

34. Peroxisomal dysfunctions cause lysosomal storage and axonal Kv1 channel redistribution in peripheral neuropathy.

35. Effect of an interactive cardiopulmonary resuscitation assist device with an automated external defibrillator synchronised with a ventilator on the CPR performance of emergency medical service staff: a randomised simulation study.

36. Evaluation of relative MS response factors of drug metabolites for semi-quantitative assessment of chemical liabilities in drug discovery.

37. Sequestration of cholesterol within the host late endocytic pathway restricts liver-stage Plasmodium development.

38. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.

39. Increasing metabolic stability via the deuterium kinetic isotope effect: An example from a proline-amide-urea aminothiazole series of phosphatidylinositol-3 kinase alpha inhibitors.

40. Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors.

41. Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.

42. Characterization of the complex formed by β-glucocerebrosidase and the lysosomal integral membrane protein type-2.

43. Lysosome associated membrane proteins maintain pancreatic acinar cell homeostasis: LAMP-2 deficient mice develop pancreatitis.

44. Orally bioavailable Syk inhibitors with activity in a rat PK/PD model.

45. Mannose 6-phosphate-independent Lysosomal Sorting of LIMP-2.

46. Chronic enzyme replacement therapy ameliorates neuropathology in alpha-mannosidosis mice.

47. Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.

48. Micropreparative isolation and NMR structure elucidation of metabolites of the drug candidate 1-isopropyl-4-(4-isopropylphenyl)-6-(prop-2-yn-1-yloxy) quinazolin-2(1H)-one from rat bile and urine.

49. Discovery and profiling of a selective and efficacious Syk inhibitor.

50. Lysosomal integral membrane protein type-2 (LIMP-2/SCARB2) is a substrate of cathepsin-F, a cysteine protease mutated in type-B-Kufs-disease.

Catalog

Books, media, physical & digital resources